NCT03806894

Clopidogrel Resistance in Stroke Patients From Different Ethnicities

Prospective Study Evaluating Clopidogrel Resistance in Ischemic Stroke Patients From Different Ethnicities

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 300 (estimated)
• Sponsor: Ziv Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events. The aim of the present study is to evaluate the incidence of clopidogrel resistance in ischemic stroke patients from different ethnicities in Northern Israel and to find different strategies to overcome high platelet reactivity including clopidogrel dose adjustment or the choice of alternative agents. Quantification of platelet aggregation will be determined by vasodilator stimulated phosphoprotein (VASP) assay.

Conditions

• Clopidogrel, Poor Metabolism of
• Ischemic Stroke

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Quantification of platelet aggregation	Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay

Timeline

• Start date: 2019-10-01
• Primary completion: 2020-10-01
• Completion: 2020-12-01
• First posted: 2019-01-16
• Last updated: 2019-07-10